12 results on '"Hankui Lu"'
Search Results
2. 2016 Chinese expert consensus and guidelines for the diagnosis and treatment of papillary thyroid microcarcinoma
- Author
-
Ming Gao, Minghua Ge, Qinghai Ji, Ruochuan Cheng, Hankui Lu, Haixia Guan, Li Gao, Zhuming Guo, Tao Huang, Xiaoming Huang, Xiaoming Li, Yansong Lin, Qinjiang Liu, Xin Ni, Yi Pan, Jianwu Qin, Zhongyan Shan, Hui Sun, Xudong Wang, Zhengang Xu, Yang Yu, Daiwei Zhao, Naisong Zhang, Sheng Zhang, Ying Zheng, Jingqiang Zhu, Dapeng Li, Xiangqian Zheng, Chinese Association of Thyroid Oncology, (CATO), and Chinese Anti-Cancer Association
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Published
- 2017
- Full Text
- View/download PDF
3. Short-Term Side Effects after Radioiodine Treatment in Patients with Differentiated Thyroid Cancer
- Author
-
Liyan Lu, Fengling Shan, Wen-Bin Li, and Hankui Lu
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Drug-Related Side Effects and Adverse Reactions ,Article Subject ,lcsh:Medicine ,Pain ,030209 endocrinology & metabolism ,General Biochemistry, Genetics and Molecular Biology ,Salivary Glands ,Iodine Radioisotopes ,03 medical and health sciences ,0302 clinical medicine ,Oral administration ,Internal medicine ,Vertigo ,medicine ,Humans ,Vocal cord paralysis ,Thyroid Neoplasms ,Neoplasm Metastasis ,Adverse effect ,Thyroid cancer ,Lymph node ,Aged ,General Immunology and Microbiology ,biology ,Salivary gland ,business.industry ,Thyroid ,lcsh:R ,General Medicine ,Middle Aged ,medicine.disease ,biology.organism_classification ,Surgery ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Clinical Study ,Female ,Radiopharmaceuticals ,business - Abstract
Objectives. I-131 therapy for differentiated thyroid cancer (DTC) could induce adverse effects. The purpose of this study was to report and analyze symptoms after I-131 treatment within the hospitalization and present relevant medical intervention.Methods. I-131 doses ranging from 3.7 to 9.25 GBq (100–250 mCi) were administrated for thyroid remnant ablation or treating DTC metastases. 117 patients with DTC for I-131 therapy were monitored through the video and intercommunicating with standardized questionnaire at different time points after I-131 oral administration. Adverse effects were recorded and relevant clinical factors were analyzed.Results. Among all the 117 patients, 55 cases complained of neck’s pain or swelling and 79 cases presented with gastrointestinal symptoms. Pain or swelling of salivary gland occurred in 15 patients, headache and vertigo in 10, insomnia in 9, vocal cord paralysis in 6, fatigue or general malaise in 6, and foreign body sensation in 5. Body numbness and urinary symptoms were observed in only 1 case, respectively. Those side effects were related with sex, pre-I-131 treatment TSH levels, frequency of I-131 therapy, and lymph node metastases.Conclusions. Short-term side effects after I-131 therapy for DTC patients varied individually; severe symptoms were not uncommon but generally did not need emergent medical intervention.
- Published
- 2016
- Full Text
- View/download PDF
4. I111n-Labeled Cystine-Knot Peptides Based on the Agouti-Related Protein for Targeting Tumor Angiogenesis
- Author
-
Lei Jiang, Jennifer R. Cochran, Gang Ren, Zhen Cheng, Adam P. Silverman, Hongguang Liu, Richard H. Kimura, Hankui Lu, and Zheng Miao
- Subjects
Biodistribution ,Peptidomimetic ,Health, Toxicology and Mutagenesis ,Integrin ,Peptide ,Biology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,In vivo ,Genetics ,DOTA ,Receptor ,Molecular Biology ,030304 developmental biology ,chemistry.chemical_classification ,0303 health sciences ,Cystine knot ,General Medicine ,Molecular biology ,chemistry ,Biochemistry ,030220 oncology & carcinogenesis ,biology.protein ,Molecular Medicine ,Biotechnology - Abstract
Agouti-related protein (AgRP) is a 4-kDa cystine-knot peptide of human origin with four disulfide bonds and four solvent-exposed loops. The cell adhesion receptor integrinαvβ3is an important tumor angiogenesis factor that determines the invasiveness and metastatic ability of many malignant tumors. AgRP mutants have been engineered to bind to integrinαvβ3with high affinity and specificity using directed evolution. Here, AgRP mutants 7C and 6E were radiolabeled with111In and evaluated forin vivotargeting of tumor integrinαvβ3receptors. AgRP peptides were conjugated to the metal chelator 1, 4, 7, 10-tetra-azacyclododecane- N,N′,N″,N‴-tetraacetic acid (DOTA) and radiolabeled with111In. The stability of the radiopeptides111In-DOTA-AgRP-7C and111In-DOTA-AgRP-6E was tested in phosphate-buffered saline (PBS) and mouse serum, respectively. Cell uptake assays of the radiolabeled peptides were performed in U87MG cell lines. Biodistribution studies were performed to evaluate thein vivoperformance of the two resulting probes using mice bearing integrin-expressing U87MG xenograft tumors. Both AgRP peptides were easily labeled with111In in high yield and radiochemical purity (>99%). The two probes exhibited high stability in phosphate-buffered saline and mouse serum. Compared with111In-DOTA-AgRP-6E,111In-DOTA-AgRP-7C showed increased U87MG tumor uptake and longer tumor retention (5.74±1.60and1.29±0.02%ID/g at 0.5 and 24 h, resp.), which was consistent with measurements of cell uptake. Moreover, the tumor uptake of111In-DOTA-AgRP-7C was specifically inhibited by coinjection with an excess of the integrin-binding peptidomimetic c(RGDyK). Thus,111In-DOTA-AgRP-7C is a promising probe for targeting integrinαvβ3positive tumors in living subjects.
- Published
- 2012
5. Tumor Markers in Thyroid Carcinoma With Pulmonary Metastases After Thyroidectomy
- Author
-
Ruisen Zhu, Yunchao Gao, Hankui Lu, and Zhibin Yuan
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Biochemistry (medical) ,Clinical Biochemistry ,Thyroidectomy ,Cancer ,Gastrointestinal mucosa ,medicine.disease ,Gastroenterology ,Serology ,Thyroid carcinoma ,Internal medicine ,medicine ,Thyroglobulin ,In patient ,business ,Tumor marker - Abstract
Background The present study investigated several tumor markers in patients receiving multiple radioiodine treatments after thyroidectomy for differentiated thyroid carcinoma (DTC). Methods Serological tests for tumor markers (Tg, CFEA, CA125, CA19-9, CA72-4, and Cyfra 21-1) were performed in 57 patients with pulmonary metastases (subjects) and 76 patients without distant metastases (controls). Results Serum thyroglobulin was much higher in the subjects than in the controls (median, 595.0 versus 5.4 μg/L, P 0.05). CA72-4 was positive in 20.3% with more positive cases in those having received higher doses (cutoff dose 25.9 GBq, 36.8% versus 13.7%, P =0.003). Conclusion These tumor markers are not likely progression-related and are not recommended for the follow up of DTC patients unless other malignancies are indicated. The high sensitivity of CA72-4 may be related to radiation damage to the gastrointestinal mucosa.
- Published
- 2009
6. Incremental Value of 131I SPECT/CT in the Management of Patients with Differentiated Thyroid Carcinoma
- Author
-
Ruisen Zhu, Hankui Lu, Yan Shen, Libo Chen, Quan-Yong Luo, Yongli Yu, and Zhibin Yuan
- Subjects
Adult ,Male ,medicine.medical_specialty ,Planar Imaging ,Adolescent ,Scintigraphy ,Sensitivity and Specificity ,Iodine Radioisotopes ,Thyroid carcinoma ,Young Adult ,Text mining ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Thyroid Neoplasms ,Child ,Prospective cohort study ,Thyroid tumors ,Aged ,Tomography, Emission-Computed, Single-Photon ,medicine.diagnostic_test ,business.industry ,Thyroid ,Reproducibility of Results ,Middle Aged ,medicine.anatomical_structure ,Subtraction Technique ,Female ,Tomography ,Radiology ,Radiopharmaceuticals ,Tomography, X-Ray Computed ,Nuclear medicine ,business - Abstract
131I whole-body scintigraphy (WBS) is a highly sensitive method for the detection of differentiated thyroid tumors and metastases. However, a lack of anatomic landmarks and the physiologic accumulation of the tracer complicate interpretation of the images. This prospective study was designed to evaluate the incremental value of 131I SPECT/CT over planar WBS in the management of patients with differentiated thyroid carcinoma (DTC). Methods: Planar imaging was performed on 66 consecutive DTC patients who were considered to have locally advanced or metastatic disease after total or nearly total thyroidectomy. SPECT/CT was added for patients whose planar findings were inconclusive. The planar images were interpreted by 2 experienced nuclear medicine physicians. Interpretation of the SPECT/CT images was a consensus opinion of one of the nuclear medicine physicians and an experienced radiologist. Fusion images were considered to improve image interpretation when they better localized sites of increased 131I uptake. The final diagnosis was verified by pathologic findings, other imaging modalities, and clinical follow-up. Both site-based and patient-based analyses were performed, and the impact of SPECT/CT results on therapeutic strategy was assessed. Results: A total of 232 foci were observed by 131I WBS, including 33.2% of foci localized in the thyroid bed, 62.1% due to malignant lesions, and 4.7% caused by nonthyroidal physiologic or benign uptake or a contaminant. Overall, 37 SPECT/CT studies were performed on 23 patients, whose planar images showed 81 inconclusive lesions. Precise localization and characterization of 131I-avid foci were achieved through 131I SPECT/CT in 69 (85.2%) and 67 (82.7%) of the 81 foci, respectively. Fusion images were considered to be of benefit in 17 (73.9%) of 23 patients. The therapeutic strategy was changed in 8 (47.1%) of 17 patients. Uncommon metastatic lesions were found in 9 (13.6%) of 66 patients with regard to SPECT/CT fusion images. Conclusion: Fusion of SPECT and CT images was of incremental value over WBS in increasing diagnostic accuracy, reducing pitfalls, and modifying therapeutic strategies in 73.9% of DTC patients. As SPECT/CT techniques emerge, 131I SPECT/CT may demonstrate higher value than WBS in the management of DTC.
- Published
- 2008
7. Imaging proliferation in human leukemia-tumor bearing mice with (18)F-FLT: Comparison with (18)F-FDG PET
- Author
-
Liyan, Lu, Lei, Jiang, Haixia, Guan, Yunchao, Gao, and Hankui, Lu
- Subjects
Male ,Mice, Inbred BALB C ,Mice, Nude ,Reproducibility of Results ,Image Enhancement ,Sensitivity and Specificity ,Dideoxynucleosides ,Mice ,Fluorodeoxyglucose F18 ,Cell Line, Tumor ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,Positron-Emission Tomography ,Animals ,Humans ,Neoplasm Invasiveness ,Radiopharmaceuticals ,K562 Cells - Abstract
Leukemia threatens human life due to its uncontrolled proliferative malignancy. 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) has been suggested as a new positron emission tomography (PET) tracer for imaging tumor proliferation. The aim of the study was to investigate the usefulness of (18)F-FLT PET for imaging human leukemia-tumor bearing mice, compared with fluorine-18-fluorodesoxyglucose ((18)F-FDG PET). In vitro the experiments of (18)F-FLT and (18)F-FDG uptake were performed in K562 cell lines at various time points and radioactive tracer uptake was measured in a gamma counter. (18)F-FLT and (18)F-FDG PET imaging were performed both in the same mouse when eight tumor-bearing mice models of human chronic myeloid leukemia were established successfully by injecting K562 cells. Regions of interest were drawn over the tumor, the crossed normal tissue was regarded as background and the ratio of tumor to non-tumor counts (T/NT) in tissues was calculated. A higher uptake of (18)F-FLT (15min, 5.73±0.05%; 30min, 5.90±0.06%; 60min, 6.16±0.19%; 120min, 6.32±0.08%) than that of (18)F-FDG (15min, 1.05±0.10%; 30min, 1.11±0.14%; 60min, 1.14±0.37%; 120 min, 1.36±0.25%) was observed in K562 cells in the tracer uptake experiment. Ratios of T/NT of (18)F-FLT PET (0.5h, 5.39±0.42; 1h, 4.88±0.43; 2h, 3.81±0.38) were higher than those of (18)F-FDG PET/CT (0.5h, 0.34±0.12; 1h, 0.21±0.06; 2h, 0.13±0.05) after injection. Both uptake and T/NT differences of (18)F-FLT versus (18)F-FDG were significant (P0.05). In conclusion, (18)F-FLT and (18)F-FDG quantitative and semi-quantitative uptake measurements resulting from cell lines and PET imaging respectively suggested a promising potential of (18)F-FLT for metabolic imaging of human chronic myeloid leukemia.
- Published
- 2012
8. 111In-labeled cystine-knot peptides based on the Agouti-related protein for targeting tumor angiogenesis
- Author
-
Lei, Jiang, Zheng, Miao, Richard H, Kimura, Adam P, Silverman, Gang, Ren, Hongguang, Liu, Hankui, Lu, Jennifer R, Cochran, and Zhen, Cheng
- Subjects
Neovascularization, Pathologic ,Brain Neoplasms ,digestive, oral, and skin physiology ,Indium Radioisotopes ,Molecular Sequence Data ,Transplantation, Heterologous ,Mice, Nude ,Cystine-Knot Miniproteins ,Heterocyclic Compounds, 1-Ring ,Mice ,Cell Line, Tumor ,Animals ,Humans ,Agouti-Related Protein ,Female ,Tissue Distribution ,Amino Acid Sequence ,Glioblastoma ,Radionuclide Imaging ,Research Article - Abstract
Agouti-related protein (AgRP) is a 4-kDa cystine-knot peptide of human origin with four disulfide bonds and four solvent-exposed loops. The cell adhesion receptor integrin α(v)β(3) is an important tumor angiogenesis factor that determines the invasiveness and metastatic ability of many malignant tumors. AgRP mutants have been engineered to bind to integrin α(v)β(3) with high affinity and specificity using directed evolution. Here, AgRP mutants 7C and 6E were radiolabeled with (111)In and evaluated for in vivo targeting of tumor integrin α(v)β(3) receptors. AgRP peptides were conjugated to the metal chelator 1, 4, 7, 10-tetra-azacyclododecane- N, N', N″, N'''-tetraacetic acid (DOTA) and radiolabeled with (111)In. The stability of the radiopeptides (111)In-DOTA-AgRP-7C and (111)In-DOTA-AgRP-6E was tested in phosphate-buffered saline (PBS) and mouse serum, respectively. Cell uptake assays of the radiolabeled peptides were performed in U87MG cell lines. Biodistribution studies were performed to evaluate the in vivo performance of the two resulting probes using mice bearing integrin-expressing U87MG xenograft tumors. Both AgRP peptides were easily labeled with (111)In in high yield and radiochemical purity (99%). The two probes exhibited high stability in phosphate-buffered saline and mouse serum. Compared with (111)In-DOTA-AgRP-6E, (111)In-DOTA-AgRP-7C showed increased U87MG tumor uptake and longer tumor retention (5.74 ± 1.60 and 1.29 ± 0.02%ID/g at 0.5 and 24 h, resp.), which was consistent with measurements of cell uptake. Moreover, the tumor uptake of (111)In-DOTA-AgRP-7C was specifically inhibited by coinjection with an excess of the integrin-binding peptidomimetic c(RGDyK). Thus, (111)In-DOTA-AgRP-7C is a promising probe for targeting integrin α(v)β(3) positive tumors in living subjects.
- Published
- 2011
9. A first described chest wall metastasis from colon cancer demonstrated with (18)F-FDG PET/CT
- Author
-
Lei, Jiang, Yunchao, Gao, Shiwei, Sheng, Min, Xu, Liyan, Lu, and Hankui, Lu
- Subjects
Fluorodeoxyglucose F18 ,Positron-Emission Tomography ,Colonic Neoplasms ,Humans ,Thoracic Wall ,Tomography, X-Ray Computed - Abstract
It is well known that, haematogenous colon cancer metastases are most commonly found in the liver, less likely in the lungs through the paravertebral venous system and rarely in other organs. Sporadic clinical cases of colon cancer metastases to the abdominal wall, the thyroid or the adrenal glands have been reported. Here, we present an uncommon case of chest wall metastasis from colon cancer demonstrated with 2-fluoro [fluorine-18]-2-deoxy-D-glucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT). A 52 years old female patient was examined after she felt a swelling mass above her left breast. Tumor makers, such as serum cancer embryonic antigen (CEA) 146.22kU/L (normal range:0.00~37.0kU/L) and CA19-9 (258.16μg/L (normal range:0.00~10.0μg/L) and neuron-specific enolase (NSE) 78.2 (normal range: 0.00~17.00) were abnormally high. Chest CT revealed the soft tissue density mass on the left anterior chest wall with invasion of left 4th rib, and CT-guided biopsy showed a poorly differentiated adenocarcinoma of unkown origin. The patient was then referred for the (18)F-FDG-PET scan which was performed one hour after the intravenous injection of 370MBq of (18)F-FDG (Discovery Camera, VCT, GE, USA) and showed in addition to the chest mass, abnormal (18)F-FDG accumulation in both lungs, left supraclavicular and peritoneal lymph nodes. Furthermore, high (18)F-FDG uptake was detected in the sigmoid. Pathology findings from colonoscopy confirmed that this was a sigmoid colon adenocarcinoma. So far, chest wall metastasis from colon cancer as an initial finding has not been reported. Usually, an initial chest wall mass is hardly suspected to be a colon cancer metastasis. Abnormal serum tumor markers such as CEA and CA19-9 supported the diagnosis of a gastrointestinal adenocarcinoma. In our case, we found high serum NSE and normal findings of bowel wall on the CT scan, thus without the positive (18)F-FDG findings, one would probably consider as first diagnosis: chest wall metastasis from lung cancer, or a neuroendocrine tumor. The unusual finding in this case was that on the CT images there was no obvious local density of the intestine, no bowel wall thickening, or suspicious nodular lesions. Segmental (18)F-FDG accumulation seen in the sigmoid colon had early maximum standardized uptake value (SUV(max)) 7.3 and in 1h delayed estimation, 8.1. Colonoscopy showed that the (18)F-FDG-avid area at the colon was circular and thickened. "Hot" lesions found in both lungs, the supraclavicular and retroperitoneal lymph nodes by (18)F-FDG PET/CT scan were considered to be most probably metastases from colon adenocarcinoma. In conclusion, PET as a rather simple procedure and less dependent on bowel preparation diagnosed the primary colon cancer, its metastases and specifically a first described chest wall metastasis, while CT alone did not show the primary tumor.
- Published
- 2011
10. The role of radionuclide lymphoscintigraphy in extremity lymphedema
- Author
-
Quan-Yong Luo, Hankui Lu, Jifang Zhu, Libo Chen, Ruisen Zhu, and Zhibin Yuan
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Organotechnetium Compounds ,Sensitivity and Specificity ,hemic and lymphatic diseases ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Radionuclide imaging ,Lymphedema ,Child ,Radionuclide Imaging ,Aged ,Retrospective Studies ,Radionuclide ,business.industry ,Reproducibility of Results ,Dextrans ,General Medicine ,Middle Aged ,medicine.disease ,humanities ,body regions ,Child, Preschool ,Female ,Radiology ,Lymph Nodes ,Radiopharmaceuticals ,Nuclear medicine ,business - Abstract
The characteristics of lymphedema on radionuclide lymphoscintigraphy were studied, and the diagnostic value of radionuclide lymphoscintigraphy in lymphedema was evaluated. In this report radionuclide lymphoscintigraphy was performed in 110 cases of clinically suspected lymphedema. A retrospective study method was used to analyze the imaging results. The typical pattern of lymphedema on radionuclide lymphoscintigraphy was summarized. It was found that the characteristics of lymphedema on radionuclide lymphoscintigraphy were diverse. The most common pattern was increased radiotracer accumulation in the soft tissue and lymphatic webs. Surgery and infection dominated as the causes of lymphedema in this study. It was concluded that radionuclide lymphoscintigraphy is a useful noninvasive method for diagnosing lymphedema. It is easy to operate and provides reliable results.
- Published
- 2006
11. Tumor Markers in Thyroid Carcinoma With Pulmonary Metastases After Thyroidectomy.
- Author
-
Yunchao Gao, Hankui Lu, Zhibin Yuan, and Ruisen Zhu
- Subjects
- *
TUMOR markers , *THYROID cancer , *LUNG cancer , *THYROIDECTOMY , *METASTASIS , *CANCER patients , *SEROLOGY ,THERAPEUTIC use of iodine isotopes - Abstract
Background: The present study investigated several tumor markers in patients receiving multiple radioiodine treatments after thyroidectomy for differentiated thyroid carcinoma (DTC).Methods: Serological tests for tumor markers (Tg, CFEA, CA125, CA19-9, CA72-4, and Cyfra 21-1) were performed in 57 patients with pulmonary metastases (subjects) and 76 patients without distant metastases (controls).Results: Serum thyroglobulin was much higher in the subjects than in the controls (median, 595.0 versus 5.4 μg/L, PP>0.05). CA72-4 was positive in 20.3% with more positive cases in those having received higher doses (cutoff dose 25.9 GBq, 36.8% versus 13.7%, P=0.003).Conclusion: These tumor markers are not likely progression-related and are not recommended for the follow up of DTC patients unless other malignancies are indicated. The high sensitivity of CA72-4 may be related to radiation damage to the gastrointestinal mucosa. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
12. Incremental Value of 131I SPECT/CT in the Management of Patients with Differentiated Thyroid Carcinoma.
- Author
-
Libo Chen, Quanyong Luo, Yan Shen, Yongli Yu, Zhibin Yuan, Hankui Lu, and Ruisen Zhu
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.